KRHLB, a Korean biotechnology firm, experienced a significant drop in its stock price following the U.S. Food and Drug Administration's (FDA) decision to delay approval of its liver cancer treatment, Rivoceranib. The FDA issued a Complete Response Letter (CRL) citing manufacturing compliance issues at a Chinese production facility operated by Jiangsu Hengrui Pharmaceuticals. The issue arose from a routine Current Good Manufacturing Practice (cGMP) inspection conducted in April, which resulted in a Form 483 notice highlighting deviations from manufacturing standards. Although the FDA did not raise concerns about the drug's clinical data, the manufacturing site must resolve these issues before approval can proceed. HLB's U.S. subsidiary, Elevar Therapeutics, has requested documentation from Hengrui regarding the findings and corrective actions. The company plans to review the FDA's observations and Hengrui's remediation plan before determining next steps for resubmitting the application.
Bias read (Center): The article presents factual information about the FDA's regulatory process and the implications for HLB's drug approval without overtly favoring any political ideology. It focuses on the technical and procedural aspects of the regulatory review, maintaining a balanced tone by reporting the FDA's立场,
